Get notified of page updates
Glossary on
off
Printer Friendly Page
Combination ATR inhibitor and PARP Inhibitor in Recurrent Ovarian Cancer (CAPRI)
Clinicaltrials.gov identifier:
NCT03462342
Recurrent ovarian cancer
Combination ATR inhibitor and PARP Inhibitor in Recurrent Ovarian Cancer (CAPRI)
About the Study
This study is no longer recruiting patients.
This study will look at how well patients with recurrent ovarian, primary peritoneal or cancer respond to treatment with a known as an ATR inhibitor when combined with the Olaparib.
This Study is Open To:
This study is no longer recruiting patients.
This Study is Not Open To:
This study is no longer recruiting patients.